The Neuro-Oncology Program has been an Established Research Program since 2005. The Program is led by a basic scientist, C. Stiles(DFCI), and a clinician, R. Martuza(MGH), both of whom bring years of leadership experience to their respective roles. The central focus of the Neuro-Oncology Program has been high grade-glioma in adults. The Program has a clinical trials portfolio that offers a range of therapeutic modalities for glioma, including: radiation, tumor vaccines, oncolytic viruses and signal transduction inhibitors. There are also two signal transduction pathways identified as areas of priority: VEGF antagonists and PI3K antagonists. Pediatric neuro-oncology is a growing area of interest. Genetically simple tumors of children have historically shed light on more common, genetically complex adult tumors. One of the significant strengths of the Neuro-Oncology Program in this regard is the presence of a strong pediatric oncology program anchored at DFCI for outpatient care and CHB, a nationally recognized pediatric hospital, for inpatient services, creating a unified pediatric oncology facility that has spanned both institutions for decades. Over the next five years, a goal is to move recent genetic insights from the bench to the bedside in order to improve the standard of clinical care and enable genetically-informed clinical trials. The Program plans to develop CLIA-certified assays for all """"""""actionable"""""""" genetic lesions in high-grade glioma and to apply these assays to every tumor resected at DF/HCC hospitals. There are 93 members in the Program drawn from all seven DF/HCC member institutions. They represent 13 departments of HMS and one department of HSPH. Collectively, members receive over $22.6 million in cancer-relevant funding, of which $8.1 million was from NCI and $10 million was from other peer-reviewed sponsors. During the project period (2006 to 2010), members published 997 articles in peer-reviewed journals, of which 18% were intra-programmatic, 33% were inter-programmatic, and 21% were interinstitutional. At the time of the CCSG renewal in 2005, the Program received a merit score of """"""""excellent to very good"""""""".

Public Health Relevance

High-grade gliomas in adult patients are generally incurable. Collectively, these tumors are the third leading cause of cancer-related death among middle-aged men and the fourth leading cause of death for women between the ages of 15 and 34. The goal of the Neuro-Oncology Program is to improve the standard of care for patients with these tumors through genetically informed clinical trials (a.k.a. personalized medicine) conducted on a new generation of targeted therapeutics (a.k.a. smart drugs).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006516-49
Application #
8601450
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
49
Fiscal Year
2014
Total Cost
$82,030
Indirect Cost
$60,778
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Hu, Yanhui; Comjean, Aram; Roesel, Charles et al. (2016) FlyRNAi.org-the database of the Drosophila RNAi screening center and transgenic RNAi project: 2017 update. Nucleic Acids Res :
Hong, Theodore S; Wo, Jennifer Y; Yeap, Beow Y et al. (2016) Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Clin Oncol 34:460-8
Freedman, Rachel A; Gelman, Rebecca S; Wefel, Jeffrey S et al. (2016) Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol 34:945-52
Mohr, Stephanie E; Hu, Yanhui; Ewen-Campen, Benjamin et al. (2016) CRISPR guide RNA design for research applications. FEBS J 283:3232-8
Brunner, Andrew M; Li, Shuli; Fathi, Amir T et al. (2016) Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. Br J Haematol 175:496-504
Cox, Andrew G; Hwang, Katie L; Brown, Kristin K et al. (2016) Yap reprograms glutamine metabolism to increase nucleotide biosynthesis and enable liver growth. Nat Cell Biol 18:886-96
McKay, Tina B; Hjortdal, Jesper; Sejersen, Henrik et al. (2016) Endocrine and Metabolic Pathways Linked to Keratoconus: Implications for the Role of Hormones in the Stromal Microenvironment. Sci Rep 6:25534
Nelms, Bradlee D; Waldron, Levi; Barrera, Luis A et al. (2016) CellMapper: rapid and accurate inference of gene expression in difficult-to-isolate cell types. Genome Biol 17:201
Tan, Justin L; Fogley, Rachel D; Flynn, Ryan A et al. (2016) Stress from Nucleotide Depletion Activates the Transcriptional Regulator HEXIM1 to Suppress Melanoma. Mol Cell 62:34-46
Johnson, Shawn F; Cruz, Cristina; Greifenberg, Ann Katrin et al. (2016) CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer. Cell Rep 17:2367-2381

Showing the most recent 10 out of 303 publications